Trial · NCT06989437
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437, Phase 2, Phase 3, Recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue. Trials, record NCT06989437. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06989437
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- NCT number
- NCT06989437
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 982 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- ponsegromab, placebo
- First posted
- 2025-05-25
- Last updated
- 2026-10-14
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent change from baseline in body weight for ponsegromab compared to placebo | Baseline, Week 12 | |
| Primary | Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores | Baseline, Week 12 | Scale consists of five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher scores are associated with a better outcome. |
| Secondary | Change from baseline in non-sedentary physical activity time | Baseline, Week 12 | measured by wearable Digital Health Technology watch |
| Secondary | Overall survival | Randomization through completion of Phase 3 of the study, an average of 1 year | Outcome defined as the time from randomization to occurrence of all-cause death |
| Secondary | Change from baseline in body weight (kg) | Baseline, Week 12 and up to Week 52 | |
| Secondary | Change from baseline at Week 12 in physical activity as measured by total vector magnitude | Baseline, Week 12 | measured by wearable Digital Health Technology watch |
| Secondary | Effect on progression free survival | Randomization through completion of Phase 3 of the study, an average of 1 year | determined by Blinded Independent Central Review |
| Secondary | Effect on objective response rate | Baseline, Week 52 | determined by Blinded Independent Central Review |
| Secondary | Effect on disease control rate | Baseline, Week 52 | determined by Blinded Independent Central Review |
| Secondary | Effect on duration of response | Baseline, Week 52 | determined by Blinded Independent Central Review |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06989437
GET https://conductscience.org/api/trials/v1/NCT06989437/registered?page=2